Navigation Links
Allos Therapeutics to Present at the 2007 JMP Securities Healthcare Focus Conference
Date:11/7/2007

WESTMINSTER, Colo., Nov. 7 /PRNewswire-FirstCall/ -- Allos Therapeutics, Inc. (Nasdaq: ALTH), a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of cancer, today announced that the Company will participate in the 2007 JMP Securities Healthcare Focus Conference in Boston.

The Company's presentation will take place at 12 p.m. (Eastern) on Tuesday, November 13, 2007. There will be a live webcast of the presentation, which will be accessible through a link posted on the Allos website home page and investor relations section. The webcast will be available for replay on Allos' website through November 27, 2007.

About Allos Therapeutics, Inc.

Allos Therapeutics is a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of cancer. The Company's lead product candidate, PDX (pralatrexate), is a novel antifolate currently under evaluation in a pivotal Phase 2 (PROPEL) trial in patients with relapsed or refractory peripheral T-cell lymphoma. The PROPEL trial is being conducted under an agreement reached with the U.S. Food and Drug Administration under its special protocol assessment, or SPA process. The Company is also investigating PDX in patients with non-small cell lung cancer and a range of other lymphoma sub-types. The Company's other product candidate is RH1, a targeted chemotherapeutic agent, for which the Company expects to initiate a Phase 1 trial in patients with advanced solid tumors in the fourth quarter of 2007. For additional information, please visit the Company's website at http://www.allos.com.

Safe
'/>"/>

SOURCE Allos Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Allos Therapeutics to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Allos Therapeutics to Present at the 2007 UBS Global Life Sciences Conference
3. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
4. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
5. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
6. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
7. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
8. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
9. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
10. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
11. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 2014 The global companion diagnostics ... 2019. It is expected to grow at a ... was valued at $1.8 billion in 2013, according ... Research. , For more information regarding analysis details ... The research report, titled “Companion Diagnostics Market (Breast ...
(Date:8/29/2014)... 2014 /PRNewswire/ - iCo Therapeutics ("iCo" or "the ... results for the six months ended June 30, ... Canadian dollars and presented under International Financial Reporting ... , Announced top-line results related to ... for subjects enrolled in the Phase 2 iDEAL ...
(Date:8/29/2014)... Due to a misstatement posted by the Family ... Technology Center, LLC ( ASCTC ) was reported as an ... might benefit ALS patients. Because of ASCTC's exclusive focus ... and therapeutic applications, FRC listed ASCTC as one of several ... wish not to support research that requires the death of ...
(Date:8/28/2014)... SPIE Fellow Glenn Boreman, Professor and ... and Director of the Center for Optoelectronics and Optical ... and co-founder and Chairman of the Board of Plasmonics, ... Vice President of SPIE, the international society for optics ... recent election results at the Annual General Meeting of ...
Breaking Biology Technology:Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 2The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 3Glenn Boreman, UNC Professor and Plasmonics Co-Founder, Elected to SPIE Presidential Chain 2
... Hires ... -, ... GTS ) today announced that Luis,Clavell-Rodriguez, MD, medical director at the San ... Farber Acute Lymphoblastic Leukemia Consortium, was appointed,chairman of the board of directors. ...
... announced today that,it has initiated coverage on Synvista Therapeutics, ... of Vista Partners stated, "Synvista is one of,the best ... is conducting four Phase 2 trials in multi-billion dollar ... market, could begin to,produce revenues as early as next ...
... - Vasogen Inc.,(NASDAQ: VSGND ; TSX:VAS) today announced ... a Company overview at the Rodman & Renshaw ... 12:30 p.m. local time (6:30,a.m. ET) on Monday, ... the presentation can be accessed through Vasogen,s,website at ...
Cached Biology Technology:Triple-S Management Corporation Appoints New Non-Executive Chairman to Board; Adds New Director 2Vista Partners Initiates Coverage on Synvista Therapeutics, Inc. (AMEX: SYI) 2Vasogen to Webcast Presentation at the Rodman & Renshaw 5th Annual Global Healthcare Conference 2Vasogen to Webcast Presentation at the Rodman & Renshaw 5th Annual Global Healthcare Conference 3
(Date:8/28/2014)... called TX Invasives is now available from the Lady ... at Austin for identifying harmful non-native plant, insect and ... the United States cause about $137 billion in economic ... clog waterways, kill native plants and more. , "By ... reporting where invasive species occur, we,re more likely to ...
(Date:8/28/2014)... your neighbors than traditional cigarettes, but still release ... study from USC. , Scientists studying secondhand smoke ... exposure to harmful particles, with close-to-zero exposure to ... harmful metals in second-hand e-cigarette smoke were found ... contains high levels of polycyclic aromatic hydrocarbons ...
(Date:8/28/2014)... support of peer groups and clinicians is critical ... to recent University of Georgia research. , A ... County area determined that role models for successful ... of infants. , "Mothers who received that support ... said study co-author Alex Anderson, an associate professor ...
Breaking Biology News(10 mins):Mobile app makes ID of harmful plants, insects in Texas a snap 2Second-hand e-cig smoke compared to regular cigarette smoke 2Breastfeeding study shows need for effective peer counseling programs 2
... like to eat mussels steamed in white wine, but we also ... into the ground or tethered to rocks. But if you look ... and nutrition in a special and fascinating way. Mussels thrive in ... there. This is in no small part due to the evolution ...
... Researchers have discovered a key reason why a form ... a life-threatening phase called blast crisis. The study, led ... Cancer Center-Arthur G. James Cancer Hospital and Richard J. ... (CML) progresses when immature white blood cells lose a ...
... WASHINGTON, March 4, 2010 Ron Seely, an accomplished ... the American Chemical Society,s prestigious James T. Grady-James H. ... will be honored in San Francisco, Calif., on March ... the Society,s 239th National Meeting and Exposition. ...
Cached Biology News:Mussels -- material artists with grip 2Mussels -- material artists with grip 3Study identifies key cause of chronic leukemia progression 2Veteran Great Lakes area journalist wins prestigious American Chemical Society award 2
... Gene Inspector can perform many sophisticated DNA analysis ... much more than just another sequence analysis product. ... suite of analyses to be performed each time ... custom style sheets which specify exactly how your ...
... the first fully automated proteomics workcell. It ... with complete data tracking. It automates the ... through final protein expression and measurement. The ... a plate to any of its instruments ...
...
... structure visualization, phylogenetic tree building, sequence analysis, ... application. Retrieve sequences ... filter them in real-time Organize your ... filtering and sorting Provides up-to-date articles ...
Biology Products: